by a cathepsin C-independent mechanism. This is the first documented example of a human mutation affecting granzyme B activity and highlights the importance of cathepsin C in human NK cell function.
Abstract.
Activation of granzyme B, a key cytolytic effector molecule of NK cells, requires removal of an N-terminal pro-domain. In mice, cathepsin C is required for granzyme processing and normal NK cell cytolytic function, whereas in patients with PapillonLefèvre syndrome (PLS), loss-of-function mutations in cathepsin C do not affect lymphokine activated killer (LAK) cell function. Here we demonstrate that resting PLS NK cells do have a cytolytic defect and fail to induce the caspase cascade in target cells.
NK cells from these patients contain inactive granzyme B, indicating that cathepsin C is required for granzyme B activation in unstimulated human NK cells. However, in vitro activation of PLS NK cells with IL-2 restores cytolytic function and granzyme B activity by a cathepsin C-independent mechanism. This is the first documented example of a human mutation affecting granzyme B activity and highlights the importance of cathepsin C in human NK cell function.
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Introduction.
Natural killer (NK) cells are cytolytic lymphocytes whose function is to control infection and malignancy. Granule exocytosis delivers granzymes, a family of pro-apoptotic serine proteases, to target cells leading to the induction of caspase-dependent and caspaseindependent apoptosis. 1 Mouse granzyme B is required for the rapid induction of apoptosis in target cells. 2 However, other granzyme molecules contribute to the overall cytolytic phenotype 3 , with human cells expressing granzymes A, B, H, K and M. 1, 4 Activation of granzymes requires the removal of an N-terminal dipeptide.
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Cathepsin C, a cysteine protease also known as dipeptidyl peptidase I (DPPI), has been implicated in granzyme A and B processing. 6, 7 Cathepsin C deficient mice fail to process granzymes A and B and hence lack both NK and T-cell mediated cytolytic activity. 7 Human cathepsin C deficiency is the cause of Papillon-Lefèvre syndrome (PLS). [8] [9] [10] This is an extremely rare, autosomal recessive condition characterised by palmoplantar keratosis and severe periodontitis. In addition, skin infections and liver abscesses have been reported in PLS 10, 11 , strongly suggesting an immunodeficiency component to the disease. However, in contrast to the mouse model, IL-2 generated lymphokine activated killer (LAK) cell activity in these patients appears to be normal and granzyme B is active in PLS LAK cells. 12 Here, we have tested the requirement for cathepsin C in the processing of granzyme B in unstimulated human NK cells from PLS patients. We describe an NK cell cytolytic defect and a failure of granzyme B activation.
Study Design
Patients.
PLS patients 1 and 2 are brother and sister from a consanguineous family, family 6 in Toomes et al. 8 Both patients are homozygous for a mutation changing glycine 277 of cathepsin C to a serine (G277S). This nomenclature is that used in the structural study 13 and refers to cathepsin C with the 24 amino-acid signal peptide removed. A third family member is unaffected by PLS and has one G277S allele and one wild type allele and is referred to as the heterozygote. Blood samples from patients, the heterozygote and 
Functional studies
NK cells were phenotyped in whole blood using flow cytometry and isolated from PBMC using the NK isolation kit II (Miltenyi Biotech). NK cells were used directly or cultured for 10-14 days with 50 units/ml human recombinant IL-2 (Sigma). Whole cell lysates were assayed for cathepsin C or granzyme B activity using the colorimetric substrates Gly-Phe-pNA (Sigma) and Ac-IEPD-pNA (Calbiochem), respectively 14, 15 , or used in immunoblotting experiments. Aprotinin agarose binding was performed as described. 16, 17 Killing and caspase activation assays were performed using flow cytometry, using Results and Discussion.
The PLS patients exhibited very low levels of cathepsin C substrate hydrolysis in unstimulated and IL-2 stimulated NK cells compared to controls ( Figure 1A) , consistent with the proximity of the mutated residue to the active site of the enzyme. 13 The CD56 bright and CD56 dim NK subsets 20 from the patients and controls were indistinguishable ( Figure 1B ) and expression of CD158a, CD158b, CD94 and CD16 was also normal in the patients (Supplementary Data). In a previous report, LAK cells from PLS patients were found to have normal cytolytic activity. 12 Our results confirmed this since control, heterozygote and PLS NK cells cultured in IL-2 were able to kill K562 target cells ( Figure 1C ). The heterozygote had an intermediate level of cathepsin C activity ( Figure 1A ). However, this dosage effect was not evident in the cytoxicity assay ( Figure 1C ) since, in multiple experiments, the cytolytic activity of the PLS LAK cells was never less than the controls. Furthermore, cell lysates from IL-2 activated PLS NK cells and control NK cells contained similar levels of granzyme B activity ( Figure 1D ).
These results confirm that human LAK cells, unlike those from the mouse 7 , do not require cathepsin C for cytolytic activity or granzyme B activation. An early event in granzyme B mediated apoptosis is the induction of the caspase cascade. 1 To verify that PLS LAK cells were capable of activating the caspase cascade, we modified the killing 19 The results indicate that IL-2 stimulated NK cells from PLS patients and controls are able to rapidly induce the caspase cascade in target cells ( Figure 1E ).
The proliferation and activation induced by IL-2 provides a convenient method to generate large numbers of highly cytolytic NK cells for functional studies. NK cells are activated by T cell derived IL-2. 21 However, this is likely to be a late event in a primary immune response. We therefore analysed PLS NK cells directly, without provision of exogenous IL-2. Unstimulated PLS NK cells were not cytolytic ( Removal of the dipeptide pro-domain from several serine proteases exposes the active site to inhibitors such as aprotinin, allowing processed forms to be identified by binding to aprotinin-agarose. 16, 17 Granzyme B (which is inhibited by aprotinin 22 ) was detected in the aprotinin-bound fraction in all the IL-2 stimulated samples ( Figure 2F) consistent with the presence of enzymatically active granzyme B ( Figure 1D ). However, no granzyme B was detected in the aprotinin-bound fraction in unstimulated PLS NK Figure 2F) Figure 1A) . Interestingly, some granzyme C is processed in cathepsin C deficient mice 7 indicating that cathepsin C-independent pathways of granzyme processing are present in mouse and human. Figure 1C except that targets were labelled with CellTracker TM Orange and co-cultured with effector cells for 2 hours. Cells were then stained with PhiPhiLux TM according to the manufacturer and as described. 19 Caspase activation results in cleavage of a peptide spacer in PhiPhiLux TM and increased fluorescence. 19 The percentage of cells with increased caspase activity are shown. This experiment is representative of two separate experiments and was confirmed using patient 2 (data not shown). 
cells. Instead, granzyme B from unstimulated PLS NK cells is found only in the unbound
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Patient 2 Heterozygote
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